Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Senior Vice President of Corporate Development, Seattle Genetics
|Natasha Hernday is the Senior Vice President of Corporate Development, and a member of the Executive Committee at Seattle Genetics, Inc. She leads technology licensing, clinical & commercial collaborations, mergers & acquisitions and corporate strategy projects. Prior to joining Seattle Genetics in January, 2011, she spent more than 16 years at Amgen, in roles of increasing responsibility in research, project management and business development finance, before joining the corporate development group in 2000. While in corporate development, she was a senior member of the mergers and acquisitions team for approximately seven years, followed by two years of sell-side experience leading Amgen’s out-licensing efforts and serving on the board of two companies for Amgen’s Venture Fund. Ms. Hernday received a B.A. in Biology from University of California Santa Barbara and an M.B.A from Pepperdine University.|